Sorafenib

For research use only.

Catalog No.S7397 Synonyms: BAY 43-9006

277 publications

Sorafenib Chemical Structure

CAS No. 284461-73-0

Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.

Size Price Stock Quantity  
EUR 144 In stock
EUR 265 In stock
EUR 658 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Sorafenib has been cited by 277 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vXTmlEPTB;MD6wNFAxODNyMzFOwG0> M{HLbXNCVkeHUh?=
MONO-MAC-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWwUnp2UUN3ME2wMlAxPDF6IN88US=> NVrXXVhLW0GQR1XS
ALL-PO M4WyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfBboQ4UUN3ME2wMlA{OTh2IN88US=> MoPYV2FPT0WU
NKM-1 NGOwS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M132OWlEPTB;MD6wO|QyPiEQvF2= NXrNfXVCW0GQR1XS
CGTH-W-1 NX30dYV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMkWwNlIh|ryP MmrRV2FPT0WU
BB65-RCC NXHxc4tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwNEewO|Mh|ryP M3GzbHNCVkeHUh?=
NOS-1 M{K3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[wTldKSzVyPUCuOVY{PiEQvF2= MWfTRW5ITVJ?
SH-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPxTWM2OD1yLk[1OlE{KM7:TR?= NYLOSXA3W0GQR1XS
HOP-62 M4PtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvTe|dKSzVyPUCuPFUxQDhizszN MmfGV2FPT0WU
HCC2998 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDSRolKSzVyPUCuPFg5OThizszN NXyzSI5JW0GQR1XS
GDM-1 M4[ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P1OWlEPTB;MD65NFY6QCEQvF2= M4LibHNCVkeHUh?=
KM12 M{S4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorxTWM2OD1zLkCyNFk5KM7:TR?= M3PaS3NCVkeHUh?=
LB2518-MEL MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwMkC4NFkh|ryP MX3TRW5ITVJ?
NCI-H1436 MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvUTWM2OD1zLkKxOlc5KM7:TR?= M2TTUHNCVkeHUh?=
EM-2 M3nn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i3fWlEPTB;MT6zOVU4QCEQvF2= NYfTN3N4W0GQR1XS
LAMA-84 Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwM{e2OFgh|ryP M17ISXNCVkeHUh?=
KG-1 NVH1emo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnaTWM2OD1zLkS3PVM2KM7:TR?= MlXNV2FPT0WU
A388 MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\QUHpQUUN3ME2xMlU6OTZ3IN88US=> MVLTRW5ITVJ?
no-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPhUlVGUUN3ME2xMlYyPzJ4IN88US=> NUj2WVNOW0GQR1XS
SF126 NV\yWGpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfXTWM2OD1zLk[zPFEzKM7:TR?= M1PuNHNCVkeHUh?=
MEG-01 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXnTWM2OD1zLkiwPVgh|ryP MmC3V2FPT0WU
A3-KAW M{LTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXm[2lKSzVyPUGuPFg1OiEQvF2= M4ryfXNCVkeHUh?=
D-247MG M3[1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn71TWM2OD1{LkG0OFgh|ryP NHrVdmdUSU6JRWK=
OVCAR-4 NWWzOFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LYNGlEPTB;Mj6yNVM6OyEQvF2= M3TQOnNCVkeHUh?=
NCI-SNU-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C0cWlEPTB;Mj6zNVYzKM7:TR?= NWqzN2dCW0GQR1XS
NCI-H2171 M{nzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjwTWM2OD1{LkO5O|Y1KM7:TR?= NGDZeZdUSU6JRWK=
SIG-M5 NX;YeXlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n5bmlEPTB;Mj60NlI1OiEQvF2= MWLTRW5ITVJ?
BE-13 M3\BT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPZVmdDUUN3ME2yMlY6PjB7IN88US=> NUPKV5V5W0GQR1XS
K052 NV\PcoRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPUTWM2OD1{Lke0OlE3KM7:TR?= NEfkXWNUSU6JRWK=
L-540 NIfRZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwN{W3PFkh|ryP NVq1[oJ2W0GQR1XS
KMOE-2 NIPENG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH1TWM2OD1{LkixN|Uh|ryP MnHDV2FPT0WU
MFH-ino Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;TbmlEPTB;Mj65NlE5PSEQvF2= M3;rPHNCVkeHUh?=
HL-60 M{LxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;FTWM2OD1|LkC2Nlk6KM7:TR?= MX\TRW5ITVJ?
HCC2218 NEmxZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj4WoZKSzVyPUOuNVIxODNizszN NEnXPINUSU6JRWK=
TE-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M174e2lEPTB;Mz6xN|E3OiEQvF2= NYfweFRRW0GQR1XS
MZ1-PC NHTuOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwNEe1NFkh|ryP MXTTRW5ITVJ?
MRK-nu-1 M3OwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzsTWM2OD1|Lk[xOFY5KM7:TR?= NVXIWo9wW0GQR1XS
MZ7-mel M1TsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV74VmpkUUN3ME2zMlY3ODl7IN88US=> MVjTRW5ITVJ?
BC-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HFR2lEPTB;Mz63OFAzKM7:TR?= MV7TRW5ITVJ?
ST486 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDyTWM2OD1|LkizOlc{KM7:TR?= NV3ReFJpW0GQR1XS
KS-1 NYfTdHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3icFNKSzVyPUOuPFgyQThizszN MonMV2FPT0WU
SK-NEP-1 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HXTmlEPTB;ND6xOlgyPSEQvF2= MYTTRW5ITVJ?
BC-3 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TFXGlEPTB;ND6yN|M6OSEQvF2= NEDBNZdUSU6JRWK=
NCI-H1581 M4rSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHCS2hKSzVyPUSuNlg4QThizszN NF3tRWxUSU6JRWK=
MHH-PREB-1 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;ke3hJUUN3ME20MlQxPDh2IN88US=> NE\wfVZUSU6JRWK=
NOMO-1 M4nZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33kfWlEPTB;ND60PFkxPSEQvF2= MY\TRW5ITVJ?
QIMR-WIL NUHPUoRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH4NpN7UUN3ME21MlA4Ojl2IN88US=> MoTTV2FPT0WU
SF539 M{X6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32xWmlEPTB;NT6xN|IzPyEQvF2= NHLhSoFUSU6JRWK=
TE-12 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T4NmlEPTB;NT6yOFkzQSEQvF2= M3iwO3NCVkeHUh?=
NCI-H510A M2roV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL4cphKSzVyPUWuOFE3QDVizszN MYLTRW5ITVJ?
JAR NVrZ[WN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[weI8zUUN3ME21MlUxQDJ2IN88US=> NYjmZVFFW0GQR1XS
no-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm3dmxKSzVyPUWuO|M2PjhizszN MXrTRW5ITVJ?
BV-173 NYD4O45IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PRVWlEPTB;NT65OVY5OiEQvF2= M3Ls[nNCVkeHUh?=
SR MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf6Tm9KSzVyPU[uNFA3PzhizszN M1;YfHNCVkeHUh?=
MOLT-16 NF3PVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi4U4FHUUN3ME22MlI2OjZ4IN88US=> Ml25V2FPT0WU
MZ2-MEL Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTZwM{G4N|kh|ryP NFHSSFhUSU6JRWK=
SW954 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD1TWM2OD14LkS1PFY3KM7:TR?= M4rROHNCVkeHUh?=
ML-2 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3remFKSzVyPU[uOVI5PDlizszN MULTRW5ITVJ?
OCI-AML2 Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDncHJKSzVyPU[uOlExPjJizszN M3LRUXNCVkeHUh?=
SIMA MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTdwMECxNFEh|ryP M2n6[XNCVkeHUh?=
DOHH-2 NFLx[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzve2xKSzVyPUeuNFU3PzZizszN Mn7EV2FPT0WU
697 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPNZ3kzUUN3ME23MlA2QTh7IN88US=> NVj5NlFIW0GQR1XS
NB1 NFrhfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXve3lKSzVyPUeuOFA1ODdizszN M4nqTXNCVkeHUh?=
D-392MG NFfwTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X5cGlEPTB;Nz62NlY3OyEQvF2= NYnCe3FtW0GQR1XS
ES8 M3npXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrTeXc3UUN3ME23Mlc3PTB|IN88US=> MmPwV2FPT0WU
RPMI-8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETxWVhKSzVyPUeuPFQ2OTFizszN MWXTRW5ITVJ?
IST-MEL1 MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT4TWxOUUN3ME24MlQxODB{IN88US=> NWnCfpRFW0GQR1XS
NB14 NGDSfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD6TWM2OD16Lk[zNVM{KM7:TR?= MlzaV2FPT0WU
HD-MY-Z MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrBVolPUUN3ME24MlY{PzR4IN88US=> MkXoV2FPT0WU
TE-10 M1;GdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Xnb2lEPTB;OD63OlM2OyEQvF2= NF31dHhUSU6JRWK=
LC-1F MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHtO|dHUUN3ME25MlExQDN2IN88US=> MXzTRW5ITVJ?
OS-RC-2 M1ixdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCyN3dLUUN3ME25MlEyOjR|IN88US=> NVW3UGRZW0GQR1XS
NCI-SNU-16 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXVTGdpUUN3ME25MlIyODJ4IN88US=> NHPjT3JUSU6JRWK=
SHP-77 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLrUnlKSzVyPUmuO|E3PjJizszN MUTTRW5ITVJ?
A4-Fuk NUDoeZdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17OR2lEPTB;OT63OVYyKM7:TR?= NYDGfZNoW0GQR1XS
NB6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jT[GlEPTB;OT63OlAzQSEQvF2= M4H0PHNCVkeHUh?=
JiyoyeP-2003 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33hdWlEPTB;MUCuOFc1PSEQvF2= NVrKd5hWW0GQR1XS
DMS-114 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLJbZFKSzVyPUGwMlU1PDFizszN NFGzbJVUSU6JRWK=
NB7 M4LOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f0UGlEPTB;MUCuO|UzPiEQvF2= Mmf4V2FPT0WU
NCI-H747 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPSTWM2OD1zMT6xNlE3KM7:TR?= NGXi[25USU6JRWK=
HH M3KwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFzLkO4O|Yh|ryP NWT2PXNGW0GQR1XS
EW-18 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfMPFJOUUN3ME2xNU46ODR2IN88US=> MWfTRW5ITVJ?
CHP-126 M2\ZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzjOoltUUN3ME2xNU46PzN6IN88US=> MmDQV2FPT0WU
NTERA-S-cl-D1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHhOGs1UUN3ME2xNk4xOjd6IN88US=> MnHlV2FPT0WU
DEL M3myZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPRTWM2OD1zMj6wPVg2KM7:TR?= NHHtbXZUSU6JRWK=
LU-139 NHr5OVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH3O49nUUN3ME2xNk42PDF|IN88US=> Mn7LV2FPT0WU
P30-OHK Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\3cWFKUUN3ME2xNk42PDd7IN88US=> Ml;vV2FPT0WU
NCI-H1522 NGnpTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\NZmR3UUN3ME2xNk44PDZizszN NGGzOphUSU6JRWK=
NCI-H1299 M3jF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\oTWM2OD1zMz6yPVEyKM7:TR?= M{i0UHNCVkeHUh?=
UACC-257 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLvTWM2OD1zMz61NVI3KM7:TR?= MVXTRW5ITVJ?
Calu-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnhTXFbUUN3ME2xN{43ODR4IN88US=> MmWyV2FPT0WU
NCI-H1882 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDhTWM2OD1zMz64OVU2KM7:TR?= NYi3UXc{W0GQR1XS
BB30-HNC NX\4cldST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4foXWlEPTB;MUSuNFYxQSEQvF2= M37w[XNCVkeHUh?=
ES1 NVXjeoNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zPVWlEPTB;MUSuNVU2OSEQvF2= M3;OcnNCVkeHUh?=
NCI-H1694 NUfkVFVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH0[WNZUUN3ME2xOE41QDFzIN88US=> MlPvV2FPT0WU
IST-SL1 NID0PWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\QXnVKSzVyPUG0Mlk3OTZizszN M{T4OXNCVkeHUh?=
ECC4 Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzHTWM2OD1zNT6wOVU5KM7:TR?= MYHTRW5ITVJ?
MDA-MB-134-VI NXrkWWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF3LkSxN|Eh|ryP NWXMPHduW0GQR1XS
SCH NX:3enpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQepZKSzVyPUG1MlQ4OjhizszN NGHoTIZUSU6JRWK=
SK-N-FI NULmNVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP4XohwUUN3ME2xOU43PTN2IN88US=> M13BUHNCVkeHUh?=
HDLM-2 M2jweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7XTWM2OD1zNj6wO|E1KM7:TR?= NHjmXFNUSU6JRWK=
Ramos-2G6-4C10 M3rxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG5TWM2OD1zNj6xNlk4KM7:TR?= M13yfnNCVkeHUh?=
EW-24 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi0fo9KSzVyPUG2MlE3PjFizszN NYfpbVdbW0GQR1XS
NCI-H2141 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mwfWlEPTB;MU[uNVg6KM7:TR?= NFXxRlFUSU6JRWK=
LC4-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jqWmlEPTB;MU[uOlEyQSEQvF2= M3TsNnNCVkeHUh?=
HT-144 NVLte|FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonCTWM2OD1zNz6wNFYh|ryP NXXPfGQ4W0GQR1XS
SK-MEL-1 NXHvSYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\3O4E3UUN3ME2xO{4xODd{IN88US=> MVvTRW5ITVJ?
SCC-15 M4PGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HL[2lEPTB;MUeuNVY{QCEQvF2= NH:4Z4pUSU6JRWK=
C8166 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H0WGlEPTB;MUeuOlg{OyEQvF2= MYPTRW5ITVJ?
GOTO MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fwNWlEPTB;MUeuPFM1PCEQvF2= NHvaO2FUSU6JRWK=
COR-L279 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn32TWM2OD1zOD6xN|YzKM7:TR?= MlHTV2FPT0WU
K-562 MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF6LkexOFMh|ryP NHPTU2xUSU6JRWK=
ES3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHGTWM2OD1zOD64NFQyKM7:TR?= M4Dl[HNCVkeHUh?=
LU-165 MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH75ZoxKSzVyPUG5MlcxODhizszN Mlf2V2FPT0WU
KM-H2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjqOHN4UUN3ME2yNE4{OTh2IN88US=> MX3TRW5ITVJ?
RL MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jNe2lEPTB;MkCuPVY6OiEQvF2= NYe4blY{W0GQR1XS
EW-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJzLkG4PFkh|ryP M1fNXXNCVkeHUh?=
A101D NUTjWFJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDtTWM2OD1{MT6zO|UzKM7:TR?= M1TkbnNCVkeHUh?=
HUTU-80 M{f2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\T[5oyUUN3ME2yNU4{QTR4IN88US=> M2nzNnNCVkeHUh?=
NCI-H23 NIHtWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJzLkO5PVIh|ryP Ml7jV2FPT0WU
PF-382 MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT6WI5KSzVyPUKxMlQ1ODNizszN NELrN4JUSU6JRWK=
LB373-MEL-D M3nnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDKU3VKSzVyPUKxMlU3OTVizszN NIi0elhUSU6JRWK=
TE-8 M{H2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DpW2lEPTB;MkGuOlM6PCEQvF2= MVfTRW5ITVJ?
TE-9 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7KOox1UUN3ME2yNU45PTF|IN88US=> NI\JfItUSU6JRWK=
Daudi NVTaPJVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS0cYtKSzVyPUKxMlk{ODRizszN MlTzV2FPT0WU
D-542MG NV3SOFdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPsUJhKSzVyPUKyMlAzPTZizszN M4fMcnNCVkeHUh?=
U-698-M NFfmcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ{LkS2NFMh|ryP NEDUdIxUSU6JRWK=
ES6 NI\2NoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPLOW1VUUN3ME2yNk44OzZ4IN88US=> Mk\vV2FPT0WU
DU-4475 NX7jbmlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLqTWM2OD1{Mz64PFk4KM7:TR?= M2T0b3NCVkeHUh?=
ECC12 NFy4Z3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELjNW5KSzVyPUK0MlI5ODNizszN M4XCVnNCVkeHUh?=
C2BBe1 NVLoO45ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHlTWM2OD1{ND6zNlM6KM7:TR?= NIH4OXhUSU6JRWK=
IST-SL2 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKwV5hnUUN3ME2yOE41OzZ{IN88US=> M{X6e3NCVkeHUh?=
DJM-1 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvGcY9ZUUN3ME2yOE42OjJzIN88US=> M2\tcXNCVkeHUh?=
DMS-153 NULreHg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe4TpRyUUN3ME2yOE45PjF2IN88US=> Ml3UV2FPT0WU
NB13 MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ3LkCyOlUh|ryP NGPC[WlUSU6JRWK=
SK-N-DZ NYryWZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PTRmlEPTB;Mk[uN|QyPCEQvF2= M1LHW3NCVkeHUh?=
COR-L88 M4f1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T4b2lEPTB;Mk[uOVc6PiEQvF2= MVrTRW5ITVJ?
LU-65 M3jw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TFNWlEPTB;Mk[uPFU{PSEQvF2= NXnwOmt6W0GQR1XS
TGBC1TKB NWHFbGNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHvTWM2OD1{Nj65PFI5KM7:TR?= NE\ld2tUSU6JRWK=
THP-1 NIXYPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy5S|dKSzVyPUK3MlIyPDFizszN MkPBV2FPT0WU
ONS-76 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T6fWlEPTB;MkeuN|MzKM7:TR?= MmjBV2FPT0WU
LC-2-ad NYTGRmVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;vTWM2OD1{Nz62NlMyKM7:TR?= MXjTRW5ITVJ?
EW-13 NVzTdGlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ7LkG3OFYh|ryP M{f1SXNCVkeHUh?=
MS-1 M4HubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zabmlEPTB;M{CuO|I4QCEQvF2= NF\qdJhUSU6JRWK=
NCI-H2227 NYXYXVFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHrTWM2OD1|MD65PFA3KM7:TR?= MnnkV2FPT0WU
LXF-289 MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLHOldKSzVyPUOxMlQ1QTJizszN MVLTRW5ITVJ?
MC116 NHXBXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPmW3I5UUN3ME2zNk4xQDJ4IN88US=> M1LOTHNCVkeHUh?=
EVSA-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\MS|ZSUUN3ME2zNk4zPTh3IN88US=> NUDYdnJVW0GQR1XS
CTB-1 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTWenBKSzVyPUOzMlEyODFizszN NUTtXIN2W0GQR1XS
COLO-320-HSR NVjYTGplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN|LkG2NFMh|ryP NVPPOoRqW0GQR1XS
NCI-H2196 NX[1T5h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfhRmJKSzVyPUOzMlI2PTdizszN NVTmd4Z2W0GQR1XS
LB2241-RCC NGe0SllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rvfGlEPTB;M{OuN|E{PSEQvF2= MmXTV2FPT0WU
LS-513 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTN|Lki2N|gh|ryP NXfRV4F7W0GQR1XS
LP-1 M3Tqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jadGlEPTB;M{OuPVk2PiEQvF2= NIj5bmtUSU6JRWK=
A253 NWLQfFJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzyXJJKSzVyPUO0MlIzQTZizszN MVLTRW5ITVJ?
SK-MM-2 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmeyTWM2OD1|ND65OFUyKM7:TR?= NWLCZXRbW0GQR1XS
NCI-H1963 NFjZWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN3LkOwO|Ih|ryP MUnTRW5ITVJ?
MMAC-SF MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDIXnlKSzVyPUO1Mlg4QDVizszN MUjTRW5ITVJ?
LB831-BLC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7LSW1KSzVyPUO2MlA3PTRizszN NYLUdYVLW0GQR1XS
WSU-NHL MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nLVGlEPTB;M{[uNVY1KM7:TR?= NFHzflVUSU6JRWK=
CESS NUfPOFE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\hdG1KSzVyPUO2MlI5PDhizszN MYrTRW5ITVJ?
NEC8 NYTLd2FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzhTWM2OD1|Nj61PFM2KM7:TR?= MYnTRW5ITVJ?
KNS-42 NF3FUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm5OGVKUUN3ME2zO{4yOjN5IN88US=> MlfwV2FPT0WU
MHH-CALL-2 M3j5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN5LkG4NlEh|ryP NHm0WW1USU6JRWK=
K5 NFHtO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfOTWM2OD1|OD60N{DPxE1? NIPae2JUSU6JRWK=
CP66-MEL NEjGR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zSW2lEPTB;M{muNFc{OyEQvF2= M3mwbHNCVkeHUh?=
OPM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfyOJczUUN3ME2zPU45PDN{IN88US=> NY\RWXJ{W0GQR1XS
IST-MES1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETpN|VKSzVyPUSwMlMxQTZizszN MlTDV2FPT0WU
EC-GI-10 NEXlRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULvNXl2UUN3ME20NU42QDB3IN88US=> Ml\jV2FPT0WU
CTV-1 NIP4OZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml30TWM2OD12Mj64OFA3KM7:TR?= NGXWemVUSU6JRWK=
DG-75 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ZTWM2OD12Mz63OVk2KM7:TR?= M2PCd3NCVkeHUh?=
KNS-81-FD MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP0fINKSzVyPUS1MlQxPThizszN Mo\xV2FPT0WU
NCI-H82 NYK1R25[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTR3LkW3OVgh|ryP M4TUT3NCVkeHUh?=
RPMI-8866 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjHTWM2OD12Nj6xPFc{KM7:TR?= MYjTRW5ITVJ?
ACN MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TkN2lEPTB;NE[uOFM1KM7:TR?= M1HGZnNCVkeHUh?=
NCI-H1395 M3TL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrGO2lpUUN3ME20Ok41PzV4IN88US=> NYLCNJlzW0GQR1XS
NCI-H209 NVj2W2xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHQenFKSzVyPUS3MlE1ODVizszN Ml7CV2FPT0WU
TGW MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTR7LkC3PVEh|ryP NFXqWXdUSU6JRWK=
NCI-H748 NF7QfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\mZWlEPTB;NEmuOFc2OyEQvF2= NESwbYZUSU6JRWK=
EKVX MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK2b29xUUN3ME20PU43PjJ6IN88US=> NYjwXFh[W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

- Collapse
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+45%PEG400+50%H2O
For best results, use promptly after mixing.
0.375mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006
Smiles CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000737 Recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. January 10 2020 Phase 2
NCT03958669 Recruiting -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research November 1 2019 --
NCT03764293 Recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. June 10 2019 Phase 3
NCT03582618 Recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID